NO319331B1 - Fremgangsmate for fremstilling av terapeutisk middel bestaende av antigenspesifikke, cytotoksiske T-celler. - Google Patents
Fremgangsmate for fremstilling av terapeutisk middel bestaende av antigenspesifikke, cytotoksiske T-celler. Download PDFInfo
- Publication number
- NO319331B1 NO319331B1 NO19964896A NO964896A NO319331B1 NO 319331 B1 NO319331 B1 NO 319331B1 NO 19964896 A NO19964896 A NO 19964896A NO 964896 A NO964896 A NO 964896A NO 319331 B1 NO319331 B1 NO 319331B1
- Authority
- NO
- Norway
- Prior art keywords
- cells
- antigen
- ctl
- vector
- cell
- Prior art date
Links
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims abstract description 58
- 239000000427 antigen Substances 0.000 title claims abstract description 48
- 108091007433 antigens Proteins 0.000 title claims abstract description 48
- 102000036639 antigens Human genes 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims description 11
- 229940124597 therapeutic agent Drugs 0.000 title claims description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 68
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 26
- 239000013598 vector Substances 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 239000003550 marker Substances 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 230000035755 proliferation Effects 0.000 claims abstract description 10
- 238000011534 incubation Methods 0.000 claims abstract description 5
- 230000002062 proliferating effect Effects 0.000 claims abstract description 4
- 238000012546 transfer Methods 0.000 claims description 13
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 2
- 108091008604 NGF receptors Proteins 0.000 claims 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 1
- 101150003725 TK gene Proteins 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 33
- 210000004698 lymphocyte Anatomy 0.000 description 27
- 208000015181 infectious disease Diseases 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 208000024908 graft versus host disease Diseases 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000000735 allogeneic effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 206010062016 Immunosuppression Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 5
- 229960002963 ganciclovir Drugs 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000001494 anti-thymocyte effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108091034120 Epstein–Barr virus-encoded small RNA Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1994/001573 WO1995031208A1 (en) | 1994-05-16 | 1994-05-16 | Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic t-cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964896L NO964896L (no) | 1996-11-18 |
| NO964896D0 NO964896D0 (no) | 1996-11-18 |
| NO319331B1 true NO319331B1 (no) | 2005-07-18 |
Family
ID=8165855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964896A NO319331B1 (no) | 1994-05-16 | 1996-11-18 | Fremgangsmate for fremstilling av terapeutisk middel bestaende av antigenspesifikke, cytotoksiske T-celler. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0804210B1 (da) |
| JP (1) | JP3288708B2 (da) |
| KR (1) | KR100219258B1 (da) |
| AT (1) | ATE228368T1 (da) |
| AU (1) | AU691501B2 (da) |
| DE (1) | DE69431808T2 (da) |
| DK (1) | DK0804210T3 (da) |
| ES (1) | ES2186686T3 (da) |
| NO (1) | NO319331B1 (da) |
| PT (1) | PT804210E (da) |
| WO (1) | WO1995031208A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063375A (en) * | 1996-09-10 | 2000-05-16 | Medical University Of South Carolina | Semiallogeneic cell hybrids and related methods for treating cancer |
| GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| KR100882445B1 (ko) | 2007-03-16 | 2009-02-09 | 울산대학교 산학협력단 | 항―４－１ｂｂ 항체를 이용한 항원 특이적 자가유래ｃｄ８＋ｔ 세포의 분리 및 증식 방법 |
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PL3591047T3 (pl) | 2012-02-09 | 2022-12-05 | Baylor College Of Medicine | Mieszanki peptydowe do wytwarzania wielowirusowych ctl o szerokiej swoistości |
| EP3350600A4 (en) | 2015-09-18 | 2019-04-17 | Baylor College of Medicine | DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992005262A1 (en) * | 1990-09-14 | 1992-04-02 | The John Hopkins University | Methods and compositions for genetic therapy and potentiation of anti-tumor immunity |
| US5529774A (en) * | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
-
1994
- 1994-05-16 JP JP52929995A patent/JP3288708B2/ja not_active Expired - Lifetime
- 1994-05-16 KR KR1019960706486A patent/KR100219258B1/ko not_active Expired - Lifetime
- 1994-05-16 EP EP94917635A patent/EP0804210B1/en not_active Expired - Lifetime
- 1994-05-16 DK DK94917635T patent/DK0804210T3/da active
- 1994-05-16 DE DE69431808T patent/DE69431808T2/de not_active Expired - Lifetime
- 1994-05-16 WO PCT/EP1994/001573 patent/WO1995031208A1/en not_active Ceased
- 1994-05-16 ES ES94917635T patent/ES2186686T3/es not_active Expired - Lifetime
- 1994-05-16 AU AU69281/94A patent/AU691501B2/en not_active Expired
- 1994-05-16 PT PT94917635T patent/PT804210E/pt unknown
- 1994-05-16 AT AT94917635T patent/ATE228368T1/de active
-
1996
- 1996-11-18 NO NO19964896A patent/NO319331B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69431808T2 (de) | 2003-09-18 |
| EP0804210B1 (en) | 2002-11-27 |
| DK0804210T3 (da) | 2003-03-10 |
| KR100219258B1 (ko) | 1999-09-01 |
| ES2186686T3 (es) | 2003-05-16 |
| JPH09507643A (ja) | 1997-08-05 |
| PT804210E (pt) | 2003-04-30 |
| EP0804210A1 (en) | 1997-11-05 |
| AU691501B2 (en) | 1998-05-21 |
| JP3288708B2 (ja) | 2002-06-04 |
| NO964896L (no) | 1996-11-18 |
| NO964896D0 (no) | 1996-11-18 |
| WO1995031208A1 (en) | 1995-11-23 |
| DE69431808D1 (de) | 2003-01-09 |
| ATE228368T1 (de) | 2002-12-15 |
| AU6928194A (en) | 1995-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Glienke et al. | GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18 | |
| Sauce et al. | Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti–Epstein-Barr virus potential through both culture-dependent and selection process–dependent mechanisms | |
| Marktel et al. | Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell–depleted stem cell transplantation | |
| Amrolia et al. | Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses | |
| Heemskerk et al. | Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer | |
| US11471486B2 (en) | Selective and controlled expansion of educated NK cells | |
| Lucas et al. | Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes for recurrent, EBV‐positive Hodgkin disease | |
| US20250084145A1 (en) | Method for establishing pluripotent stem cells bearing genes encoding antigen specific t cell receptor | |
| Alici et al. | Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model | |
| Narita et al. | Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia | |
| Regn et al. | Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant | |
| CN107002039A (zh) | 使用t细胞用于培养自然杀伤细胞的方法 | |
| Pullarkat et al. | Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells | |
| US20030219463A1 (en) | T cell receptor transfer into a candidate effector cell or a precursor thereof | |
| Garland et al. | The use of Teflon cell culture bags to expand functionally active CD8+ cytotoxic T lymphocytes | |
| Rooney et al. | Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines | |
| Omer et al. | Chimeric antigen receptor signaling domains differentially regulate proliferation and native T cell receptor function in virus-specific T cells | |
| Smits et al. | Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells | |
| Bollard et al. | Immunotherapy targeting EBV-expressing lymphoproliferative diseases | |
| Kurihara et al. | Potential immunogenicity of adult T cell leukemia cells in vivo | |
| Zhou et al. | CD123 redirected multiple virus-specific T cells for acute myeloid leukemia | |
| EP0804210B1 (en) | Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic t-cells | |
| Managlia et al. | Interleukin‐7 signalling is sufficient to phenotypically and functionally prime human CD4+ naïve T cells | |
| Mukherji et al. | Cell-mediated amplification and down regulation of cytotoxic immune response against autologous human cancer. | |
| Dunnion et al. | Human antigen‐presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour‐associated antigens to cytotoxic T cells in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |